Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Launched by ARRAY BIOPHARMA, NOW A WHOLLY OWNED SUBSIDIARY OF PFIZER · May 31, 2011
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically/ cytologically confirmed, advanced non resectable solid tumors
- • Measurable or non-measurable, but evaluable disease as determined by RECIST
- Exclusion Criteria:
- • Patients with primary CNS tumor or CNS tumor involvement.
- • Diabetes mellitus
- • Unacceptable ocular/retinal conditions
About Array Biopharma, Now A Wholly Owned Subsidiary Of Pfizer
Array Biopharma, now a wholly owned subsidiary of Pfizer, is a biopharmaceutical company dedicated to the discovery and development of innovative targeted therapies for the treatment of cancer. With a focus on precision medicine, Array leverages its extensive expertise in drug development and molecular biology to advance a robust pipeline of potential therapeutics. The company is committed to improving patient outcomes through rigorous clinical research and collaboration, aiming to deliver breakthrough treatments that address unmet medical needs in oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Greenville, South Carolina, United States
Houston, Texas, United States
Toronto, Ontario, Canada
Boston, Massachusetts, United States
Detroit, Michigan, United States
New York, New York, United States
Essen, , Germany
Heidelberg, , Germany
Utrecht, , Netherlands
Singapore, , Singapore
Barcelona, Catalunya, Spain
Bellinzona, , Switzerland
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
1-800-718-1021
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials